Skip to main content

COVID 19 Updates from RheumNow

Graduation

Congratulations! 

Years of training and work, all your efforts and overcoming hurdles have culminated in where you are today – on the verge of a new life, a new plan and possibly a new career.

High Dose Anakinra Effective in COVID-19

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs.

The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice.

RheumNow Podcast - COVID Kids and Men (5.15.20)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

CDC on Pediatric Multi-System Inflammatory Syndrome

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.

Plaquenil Does Not Protect Lupus Patients from COVID-19

Annals of Rheumatic Disease reports on an analysis of lupus (SLE) patients that shows COVID-19 infection rates were similar between those lupus patients who were taking hydroxychloroquine (HCQ) and those not taking HCQ. 

TNR Grand Rounds - What does COVID-19 have to do with Lupus?

Last night's Tuesday Nite Rheumatology featured Dr.

Our Privilege

Another lonely locked-down day. Seems like months. Rent is due, phone and EMR fees next week. Loan is pending. Seems impossible to treat complex diseases without touch and only computer screen rapport.

RheumNow Podcast – The Beat Goes On (5.8.20)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Safe Practices for Outpatient Appointments

As many parts of the country are lifting restrictions for businesses and allowing them to re-open, doctors are asking what they should do to keep themselves, their staff, and their patients safe.  As rheumatologists, we have vulnerable patients who are at high risk for complications from COVID19;

COVID-19 and Thrombotic Complications

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection.

Social

Interview w/ Private Practice Rheums on Covid - Drs. Herb Baraf and Danny Ricciardi. DC & Brooklyn Docs wrangle technology, Telehealth, Return to normal, the future and more. Watch it here>> https://t.co/TaMbiF9MLC or listen on iTunes or here>> https://t.co/G7sR23bwLW

Dr. John Cush RheumNow( View Tweet)

3 weeks ago
Why are more MEN (severely?) affected in COVID-19? Men have higher levels of circulating ACE2 (unrelated to ACEi or ARB HTN meds) based on a Biobank study of 1485 men, 537 women. ACE2 is found in lungs, heart, kidneys, vessels & testes https://t.co/CWXevTNYWm

Dr. John Cush RheumNow( View Tweet)

3 weeks 1 day ago
A new feature of COVID-19; "Covid toes" manifest as multifocal, asymmetric, erythema, ecchymoses, ischemic changes that blister or appear vasculitic. The toes, heel and soles can be affected. Healing in 12-20 days. https://t.co/Isqn9ebnQj

Dr. John Cush RheumNow( View Tweet)

3 weeks 2 days ago
Anakinra studied in COVID(+) ARDS (nonICU) pts w/ high CRP L or ferritin; 29 high dose Anakinra vs 17 controls. At day 21, more survival with anakinra 90% vs. Controls 56% (p=0·009). Anakinra also more improved CRP+resp function (72 vs 50%) https://t.co/wxjlQG44Oc

Dr. John Cush RheumNow( View Tweet)

3 weeks 3 days ago
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv

Dr. John Cush RheumNow( View Tweet)

3 weeks 3 days ago
European Medicines Agency (EMA), FDA and Health Canada have all issued warnings about the use of hydroxychloroquine & chloroquine in coronavirus, stating they should only be used in drug studies or hospitalized pts. https://t.co/HT39sT31Rq

Dr. John Cush RheumNow( View Tweet)

3 weeks 5 days ago
American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://t.co/pidOduwnDb

Dr. John Cush RheumNow( View Tweet)

3 weeks 6 days ago
COVID-19 Does alot of Damage via thrombotic complications - a role for complement or autoantibody mediated thrombotic microangiopathy? #COVID19 https://t.co/33R8WxE5C0

Dr. John Cush RheumNow( View Tweet)

3 weeks 6 days ago
Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome” https://t.co/FYsr77a68Z Meeting ID: 934 0443 3549

Dr. John Cush RheumNow( View Tweet)

3 weeks 6 days ago
“Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM “ As more people want SARS-CoV2 antibody testing, I am afraid this will give people a false sense of security ⁦@RheumNow⁩ ⁦@ACRheum⁩ NCBI - NLM - NIH https://t.co/vkjWRJQV27
3 weeks 6 days ago
×